IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals (IONS) is a US‑based biotechnology company specialised in antisense oligonucleotide (ASO) therapeutics — short strands of RNA designed to modulate gene expression. With a market capitalisation of about $11.42 billion, Ionis operates a platform-driven model: it advances a pipeline across neurology, cardiometabolic and rare diseases while partnering with larger pharma firms for development, regulatory and commercialisation support. Revenue typically comes from milestone payments, licensing fees and royalties rather than steady product sales, which can make financials lumpy. The company’s science-driven approach offers the potential for targeted medicines where conventional drugs struggle, but the path from early research to approved therapy is lengthy and uncertain. Investors should expect clinical trial binary events, regulatory dependency and periodic volatility. This profile is for educational purposes only and is not investment advice; prospective investors should consider their risk tolerance and seek personalised advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Ionis Pharmaceuticals’ stock, anticipating it will rise above its current price.
Financial Health
Ionis Pharmaceuticals is achieving strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IONS
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Antisense Platform
A platform approach can create multiple development candidates from one technology, which investors may find compelling though outcomes vary and timelines are long.
Partner Deals Matter
Collaborations with larger pharma provide funding and commercial reach, but revenues often depend on milestone timing and partner strategy.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions can significantly move the share price, but those events also carry binary downside risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
